PCM
IBRX icon

Penserra Capital Management’s ImmunityBio IBRX Stock Holding History

Penserra Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,950
Closed -$87K – 1439
2021
Q3 		$87K Buy
8,950
+210
+2% +$2.31K ﹤0.01% 847
2021
Q2 		$124K Buy
8,740
+6,275
+255% +$104K ﹤0.01% 743
2021
Q1 		$58K Sell
2,465
-25
-1% -$648 ﹤0.01% 794
2020
Q4 		$33K Buy
+2,490
New +$24K ﹤0.01% 757

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Penserra Capital Management's IBRX Position: Q4 2021 in Review

Penserra Capital Management sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 8,950 shares — an estimated $87K sold.

Penserra Capital Management first reported a position in IBRX in Q4 2020 and held it in 4 quarters. The position peaked at $124K in Q2 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

  • Penserra Capital Management reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 8,950 ImmunityBio shares in Q4 2021, an estimated $87K.
  • Penserra Capital Management first reported a position in ImmunityBio in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's ImmunityBio position peaked at $124K in Q2 2021.
  • 141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.